Topas Therapeutics has almost doubled its series B round to $48m thanks to an extension backed by all of its shareholders.

Topas Therapeutics, a Germany-based developer of treatments for autoimmune diseases based on research at University of Hamburg, has extended its series B round by €18m ($22m) thanks to its existing investor base. These shareholders are European Molecular Biology Laboratory’s EMBL Ventures, commercialisation firm Epidarex Capital, drug discovery company Evotec, pharmaceutical firm Boehringer Ingelheim’s Venture Fund,…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.